ProductsResearch & Development

As of December 2019

Brand NameLaunchIndicationsLicensor
1Nobelzin®Apr 2008Wilson’s diseaseTeva
2Lunabell® LDJul 2008dysmenorrheaJanssen
3Nobelbar®Dec 2008neonatal seizures,
status epilepticus
In-house
4Fostoin®Jan 2012status epilepticus,
prevention of postoperative seizures, etc.
Pfizer
5Gliadel®Jan 2013malignant gliomaEisai
6Indacin®Jan 2013patent ductus arteriosus of prematurityLundbeck
7Cosmegen®Jan 2013Wilms’ tumor,
choriocarcinoma,
pediatric solid malignant tumor, etc.
Lundbeck
8Lunabell® ULDSep 2013dysmenorrheaJanssen
9Alabel®Sep 2013diagnosis of malignant gliomamedac
10Unitalc®Dec 2013prevention of recurrent malignant pleural effusionNovatech
11Respia®Dec 2014apnea of prematurityNippon Boehringer
(co-development)
12Rapalimus®Dec 2014lymphangioleiomyomatosisPfizer
13Zanosar®Feb 2015gastroenteropancreatic neuroendocrine tumor Keocyt
14Nobelzin®Mar 2017HypozincemiaIn-house
15Rapalimus® GelJun 2018angiofibromaOsaka Univ/
In-house
16TITANBRIDGE®
(medical device)
Jul 2018adductor spasmodic dysphoniaTRI (Translational Research Center for Medical Innovation)
17Jemina®Oct 2018dysmenorrheaIn-house
18Retympa®250μg SetDec 2019tympanic membrane perforationTRI/
Kaken
Page top